Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy

Impact of Neoadjuvant Chemotherapy on Locoregional Surgical Treatment of Breast Cancer

(2015) Eleftherios P. Mamounas   ANNALS OF SURGICAL ONCOLOGY

Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential

(2015) Koen van de Ven et al.   Immunotherapy

Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies

(2014) Alfredo Berruti et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Consensus guidelines for the detection of immunogenic cell death

(2014) Oliver Kepp et al.   OncoImmunology

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)

(2013) G. G. Steger et al.   ANNALS OF ONCOLOGY

Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma

(2013) Chiharu Tabata et al.   BMC CANCER

Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer

(2013) Tobias Arnold et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1-Mediated Immune Suppression

(2013) S. T. Haile et al.   JOURNAL OF IMMUNOLOGY

HMGB1 Levels Are Increased in Patients with Juvenile Idiopathic Arthritis, Correlate with Early Onset of Disease, and Are Independent of Disease Duration

(2013) H. Schierbeck et al.   JOURNAL OF RHEUMATOLOGY

Unknown

(2013) Daolin Tang et al.   MOLECULAR MEDICINE

Unknown

(2013) Hogyoung Kim et al.   MOLECULAR MEDICINE

Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients

(2012) Yvonne Nadine Fahmueller et al.   INTERNATIONAL JOURNAL OF CANCER

Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity

(2012) Daniel J. Antoine et al.   JOURNAL OF HEPATOLOGY

Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone

(2012) Naoe Goto et al.   LEUKEMIA & LYMPHOMA

Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy

(2012) Nikolaus Kohles et al.   TUMOR BIOLOGY

Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy

(2012) Oliver J. Stoetzer et al.   TUMOR BIOLOGY

Circulating apoptotic and necrotic cell death markers in patients with acute liver injury

(2011) Darren G. N. Craig et al.   LIVER INTERNATIONAL

High-mobility group box 1 and cancer

(2010) Daolin Tang et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2

(2010) S. Huber et al.   BLOOD

Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway

(2010) L. Zitvogel et al.   CLINICAL CANCER RESEARCH

Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology

(2009) Martijn A. Nolte et al.   IMMUNOLOGICAL REVIEWS

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions

(2008) A. Berruti et al.   ONCOLOGIST